Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLCGlobeNewsWire • Monday
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/02/26
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesGlobeNewsWire • 08/12/26
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue EstimatesZacks Investment Research • 05/12/26
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesGlobeNewsWire • 05/12/26
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2GlobeNewsWire • 04/17/26
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 04/01/26
Cancer Stocks to Buy as Innovation Reshapes Global Oncology MarketZacks Investment Research • 03/26/26
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewsWire • 03/23/26
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/17/26
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceGlobeNewsWire • 03/02/26
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate UpdatesGlobeNewsWire • 01/08/26
Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/13/25
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial ResultsGlobeNewsWire • 11/13/25
Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC TranscriptSeeking Alpha • 11/11/25
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual MeetingGlobeNewsWire • 11/07/25
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual MeetingGlobeNewsWire • 11/07/25
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual MeetingGlobeNewsWire • 10/30/25
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual MeetingGlobeNewsWire • 10/03/25